Vince Wacher

Vince Wacher is a biotechnology/pharmaceutical industry professional with 25 years of experience successfully leading corporate strategy, partnering, research, product development, and intellectual property programs for start-ups, small companies and new business units within large companies. Prior to his role with Synthetic Biologics Inc., Vince was CEO of Verva Pharmaceuticals Ltd., where he advanced a repurposed medicine to successful Phase 2 clinical proof-of-concept testing in type 2 diabetes and discovered a new mitochondrial mode-of-action with expansion applications in NAFLD/NASH, weight loss and mitochondrial diseases. Vince has designed, implemented, and/or analyzed discovery, preclinical and clinical programs in diverse therapeutic areas, including metabolic, cardiovascular, gastrointestinal, oncology, infection, immunosuppression, drug delivery and drug repurposing. He received an Eastman Business Builder Award in 2004 for his work with Eastman Chemical Company in advancing their drug delivery technologies. Vince graduated with the University Medal in chemistry from the University of NSW and received his PhD from the University of California, Berkeley, where he worked in pesticide chemistry and toxicology. He transitioned into the pharmaceutical industry as a post-doctoral scholar in pharmacokinetics and metabolism with Dr. Leslie Z. Benet at the University of California, San Francisco.​